

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Dario NERI et al. Serial No.: 09/194,356 Group Art Unit: 1642 Filed: September 2, 1999 Examiner: A.M. HARRIS For: ANTIBODIES TO ED-B DOMAIN OF FIBRONECTIN, THEIR CONSTRUCTION AND USES INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98 Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Sir: This information disclosure statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 as follows: Timing and Fees \boxtimes Under 37 C.F.R. § 1.97(b), no fee or statement is required for filing this information disclosure statement is filed: within three months of the filing date of a national application other than a CPA under § 1.53(d); within three months of the actual filing date of the national phase of a PCT application; OR \boxtimes before the mailing of a first substantive office action (including after filing of an RCE).

specified in 37 C.F.R. § 1.97(b), but before the mailing date of:

termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2);

Under 37 C.F.R. § 1.97(c), this information disclosure statement is filed after the periods

a notice of allowance under 37 C.F.R. § 1.311; and

a final rejection under 37 C.F.R. 1.113;

OR

		is acco	empanied by:
			the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR
			a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).
			R. § 1.97(d), this information disclosure statement is filed after the mailing lowing actions which have not been withdrawn:
			a final action under 37 C.F.R. § 1.113;
			termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR
			a notice of allowance under 37 C.F.R. § 1.311;
	AND i	s filed o	on or before payment of the issue fee; AND is accompanied by:
			the statement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of \$180.00 under 37 C.F.R. § 1.17(p).
Statem	nents Ur	nder 37	C.F.R. 1.97(e)
			Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or
			No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.
Cited 1	Material	<u>ls</u>	
		ancesto	of materials listed but not attached were cited in benefit (35 U.S.C. § 120) or application Serial No, on Form 892 by the Examiner and/or Form by the applicant; see 37 C.F.R. § 1.98(d).
		-	s of materials listed but not attached were cited in an international search dated

	\boxtimes	Copies of the materials listed are attached (except for the foregoing).						
Non-F	English I	Language References						
		An English-language search report or equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s).						
		A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below:						
		 X = document of particular relevance when it is taken alone Y = document of particular relevance when it is combined with another such document 						
		A = document defining the general state of the art						
		O = non-written disclosure P = intercalated document						
		T = document cited to understand the theory or principle underlying the invention						
		E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date						
		D = cited in the application						
		L = cited for another reason						
		& = publication of member of same patent family						
		Translation of other relevant information on foreign search report						
		[insert necessary translation here]						
Other	Informa	ution_						
Pavme	ent of Fe	ees Due (If Any):						
	•	ck for \$ covering the fee identified above is attached.						
	Please	charge to Deposit Account No. 13-3402 \$ for the fee identified above.						

The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

Anthony J. Zelano, Reg. No. 27,969

Attorney for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza l
2200 Clarendon Blvd. Suite 1400
Arlington, Virginia 22201
Telephone: (703) 243-6333

Facsimile: (703) 243-6410

Attorney Docket No.: ELLIS-3

Date: October 9, 2003

AJZ:bcf

K:\Ellis-3\IDS.doc

PTO/SB/08A (08-00)

a plus sign (+) inside this box

BADEMARKS	Under the Paperwork	k Reducti	on Act of 1995 no persons a	Approved for use through 10/31/2002. OMB 0651-00 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMER ns are required to respond to a collection of information unless it contains a valid OMB control num			
Substitute fo	r form 1449A/PTO			Complete if Known			
				Application Number	09/194,356		
INFOR	MATION	DISC	CLOSURE	Filing Date	September 2, 1999		
STATE	EMENT BY	Y AP	PLICANT	First Named Inventor	Dario NERI et al.		
				Group Art Unit	1642		
(u	se as many shee	ets as r	necessary)	Examiner Name	A.M. HARRIS		
Sheet	1	of	2	Attorney Docket Number	ELLIS-3		

	U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No.1	U.S. Patent Docume	nt Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY		
	<u> </u>						
		· · · · ·					
	<u> </u>						


FOREIGN PATENT DOCUMENTS								
		Foreign Patent Document				Date of Publication of	Pages, Columns, Lines,	
Examiner Initials*	Cite No.1	Office ³	Number ⁴	Kind Code ⁵ (<i>if known</i>)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T⁵
								-
, , , , , , , , , , , , , , , , , , , ,	ļ <u>-</u>							

Examiner Signature	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute f	or form 1449A/PTC)			Complete if Known
INITO	DRA TION	DIC	CL OCUDE	Application Number	09/194,356
			CLOSURE	Filing Date	September 2, 1999
STAT	EMENT B	Y AI	PPLICANT	First Named Inventor	Dario NERI et al.
				Group Art Unit	1642
(use as many she	ets as	necessary)	Examiner Name	A.M. HARRIS
Sheet	2	of	2	Attorney Docket Number	ELLIS-3

	NON PATENT LITERATURE DOCUMENTS						
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²				
	C1	DARIO NERI et al., "High-affinity Antigen Binding by Chelating Recombinant Antibodies (CRAbs)," J. Mol. Biol. (1995) 246, 367-373					
	C2	Ashley Publications Ltd., ISSN 1354-3776, "Antibodies to the ED-B domain of fibronectin, their constructs and uses," Exp. Opin. Ther. Patents (1998) 8(7):907-910					
	С3	FREDRIK NILSSON et al., "The use of phage display for the development of tumour targeting agents," Advanced Drug Delivery Reviews 43 (2000) 165-196					

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.